Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/13/2880453/0/en/TransCode-Therapeutics-Open-Letter-to-Shareholders.html
https://www.globenewswire.com/news-release/2024/04/15/2862824/0/en/TransCode-Therapeutics-Announces-FDA-Clearance-To-Initiate-Phase-1-2-Clinical-Trial-with-TTX-MC138-in-Patients-with-Advanced-Solid-Tumors.html
https://www.globenewswire.com/news-release/2024/04/03/2857023/0/en/TransCode-Therapeutics-Reports-2023-Results-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/03/28/2853993/0/en/TransCode-Therapeutics-Announces-Appointment-of-Daniel-Vlock-M-D-as-Chief-Medical-Officer.html
https://www.globenewswire.com//news-release/2024/03/11/2843809/0/en/TransCode-Therapeutics-and-Akribion-Genomics-Report-Progress-Developing-CRISPR-Derived-Technology-for-Cancer-Treatment.html
https://www.globenewswire.com//news-release/2024/03/06/2841789/0/en/TransCode-Therapeutics-To-Present-At-2024-RNA-Leaders-Europe-Congress.html
https://www.globenewswire.com//news-release/2024/02/20/2831781/0/en/TransCode-Therapeutics-Reports-Publication-of-United-States-Patent-Application-Covering-TransCode-s-RIG-I-Agonist-Immunotherapeutic.html
https://www.globenewswire.com/news-release/2024/01/31/2821553/0/en/Nasdaq-Determines-TransCode-Therapeutics-Compliance-with-Minimum-Stockholders-Equity-Requirement-and-Continued-Listing-on-The-Nasdaq-Stock-Market.html
https://www.globenewswire.com/news-release/2024/01/29/2818904/0/en/TransCode-Therapeutics-and-Debiopharm-Announce-Collaboration-to-Develop-Targeted-Nucleic-Acid-Therapeutics-for-Cancer.html
https://www.globenewswire.com//news-release/2024/01/22/2813502/0/en/TransCode-Therapeutics-Announces-Closing-of-7-25-Million-Public-Offering.html